Psychiatry

Research breakthroughs, clinical innovations, and other news

COVID-19: Managing Anxiety and Depression

COVID-19: Managing Anxiety and Depression

The outbreak of COVID-19 is challenging all of us to cope in new ways. For people with depression and anxiety, life can seem overwhelming in normal times. Rachel Yehuda, PhD, Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai...

read more
How Epidemics Affect Our Mental Health

How Epidemics Affect Our Mental Health

Craig Katz, MD, Clinical Professor of Psychiatry and Global Health, is the founder and director of Mount Sinai’s Global Mental Health Program. He organized the psychiatric response to 9/11 in New York City through an organization he co-founded, Disaster Psychiatry...

read more
How to Talk to Your Child About COVID-19

How to Talk to Your Child About COVID-19

Discussing difficult topics with children can be uncomfortable and this pandemic is no exception. Aliza Pressman, PhD, co-Founding Director and Director of Clinical Programming for the Mount Sinai Parenting Center, shares information parents and guardians can use as...

read more
COVID-19: Coping and Resiliency Skills

COVID-19: Coping and Resiliency Skills

As the outbreak of COVID-19 spreads throughout the greater New York area, people are adjusting to radical changes in their daily life. Businesses are closed, people are working from home—if they are able to work at all—and kids are trying to learn at home. It’s a...

read more
Five Things to Know About Esketamine

Five Things to Know About Esketamine

In March 2019, intranasal esketamine—a form of ketamine marketed as SPRAVATO™ CIII Nasal Spray*—was approved by the U.S. Food and Drug Administration (FDA) to treat patients with treatment-resistant depression (TRD). James Murrough, MD, PhD, Director of Mount Sinai’s...

read more